The U.S. Food and Drug Administration has approved JASCAYD, the first new treatment for adults with idiopathic pulmonary fibrosis in over a decade [2].
This development marks a significant shift in the treatment landscape for idiopathic pulmonary fibrosis (IPF), a chronic lung disease where existing therapies have been limited [1, 4]. The arrival of new options aims to address critical unmet needs and improve overall lung function for patients.
Boehringer Ingelheim's JASCAYD, also known as nerandomilast, represents the first addition to the IPF treatment arsenal in more than 10 years [2]. Prior to these recent advancements, only three therapies for the condition had been approved by the FDA [5].
Other pharmaceutical developers are also advancing late-stage candidates. United Therapeutics is preparing an FDA filing for Tyvaso, an inhaled treprostinil. The drug achieved a second phase 3 success for IPF [1]. Data from the phase 3 TETON-2 trial showed that Tyvaso provided a significant improvement in forced vital capacity compared to a placebo [4].
Smaller-scale research continues to progress alongside these major filings. Rein Therapeutics provided a clinical trial update for its phase 2 RENEW study of LTI-03 [3]. This specific study enrolled eight patients to evaluate the drug's efficacy in treating the disease [3].
These combined efforts from multiple companies suggest a diversifying approach to treating lung scarring, ranging from inhaled medications to new systemic chemical compounds.
“JASCAYD is the first new treatment option for adults with IPF in over a decade.”
The approval of JASCAYD and the positive phase 3 results for Tyvaso signal the end of a decade-long stagnation in IPF pharmacology. By introducing diverse mechanisms of action—such as inhaled treprostinil and nerandomilast—clinicians now have more tools to slow lung function decline, potentially shifting the standard of care from simple maintenance to more aggressive disease management.
